Indigenous Gene Editing Technology to Aid Cheaper, Commercial Crop Breeding

India's Indigenous Genome-Editing Leap: CRISPR Competitor or Pipe Dream?

In a move that could redefine India's crop improvement programs, the Indian Council of Agricultural Research’s (ICAR) Central Rice Research Institute has patented a new genome-editing (GE) tool based on TnpB proteins, offering a homegrown alternative to the globally dominant CRISPR-Cas systems. The indigenous tool, secured under a 20-year patent in September 2025, promises to cut the cost and complexity of developing high-yield, climate-resilient crops by eliminating reliance on internationally monopolized technologies. It is not merely a scientific breakthrough—it is also an economic and strategic play in a $165.7 billion global bioeconomy. But will this innovation make it from the lab to the field?

Breaking the CRISPR Glass Ceiling

Until now, India’s promising strides in genome editing, such as the CRISPR-Cas-engineered improvements to Samba Mahsuri and MTU-1010 rice varieties, have remained hamstrung by royalty-heavy dependencies on foreign intellectual property. Licensing fees payable to the Broad Institute and Corteva, among others, posed a persistent financial obstacle to rolling these varieties out for commercial cultivation. By leveraging the hypercompact nature of TnpB proteins—at just 408 amino acids—Indian scientists claim to have evaded the intricate legal web surrounding CRISPR technologies. TnpB’s ability to edit plant DNA without introducing foreign genes also sidesteps the controversy over genetically modified organisms (GMOs) in India.

This tool, indigenous at its core, represents a departure from the earlier pattern of "global import, local adaptation" that dominated India's GE research efforts post-2017. Unlike the institution-specific licensing structure of CRISPR, ICAR’s TnpB is being positioned as a freely deployable alternative for Indian public-sector breeding programs. If adopted widely, it could trigger a domino effect by reducing crop improvement costs while empowering smaller seed companies and resource-poor farmers.

The Machinery Behind TnpB

The scientific promise of TnpB rests on its simplicity. While the CRISPR-Cas9 protein complex is bulky and demands tissue culture methods—an infrastructure-intensive constraint—TnpB can be introduced directly into plant cells using viral vectors, speeding up development cycles. Its precision can target DNA sequences specific to traits like drought resistance and pest immunity without incurring the complexity of transgenic methods.

Yet the real innovation might lie in ICAR’s decision to patent this technology for global markets. India has simultaneously filed for international protection, signaling an ambition far beyond domestic use. But intellectual property alone isn’t enough. For a program of this scale to work, there will need to be robust downstream infrastructure—including trained genomic scientists, high-tech laboratories, and an efficient seed distribution network. At present, these are aspirational at best.

What the Numbers Reveal

The government’s emphasis on achieving a $300 billion bioeconomy by 2030 comes with steep challenges. Genome-editing technologies, while promising in theory, touch only a sliver of the 141 million hectares of net sown area in India. Adoption rates of genetically edited crops will depend not just on availability but also on overcoming regulatory hurdles under the stringent Plant Variety and Farmers’ Rights Protection Authority Act. Other barriers loom: gaps in biosafety approvals, operational costs for scaling lab innovations to national use, and the socio-political minefield of public trust in GE crops.

Claims that TnpB will democratize access to genome-editing tools may be overstated. Without significant public investment, it is doubtful that seed companies and agricultural researchers will have sufficient access to this platform. While eliminating CRISPR-related royalty fees could reduce costs significantly, early estimates suggest that the reduction might hover around 20–25%, just enough to soothe margins but unlikely to revolutionize outcomes in the near term.

The Regulatory and Social Minefield

India’s history with genetically modified technology provides context—and caution. Bt cotton's fraught introduction contrasts with the vehement public opposition to other genetically modified organisms, such as Bt brinjal. Gene editing, while scientifically distinct from GMOs, faces a trust deficit from consumers and activists who blur this distinction. The government’s insufficient public consultation efforts only exacerbate this.

Meanwhile, the biosafety regulatory framework, heavily skewed towards transgenic crops, lacks clarity for genome-edited varieties. A 2022 Parliamentary Standing Committee on Agriculture had noted that India's GE crop approvals were among the slowest globally, riddled with bureaucratic inertia. Can ICAR’s regulatory lobbying overcome this, or will India’s GE potential remain stymied at the policy level?

An International Comparison: South Korea's GE Success

South Korea offers a telling contrast. In 2018, the country launched a national genome-editing initiative with a $200 million public grant, focusing on crops like rice and barley. What set Korea apart was not just the funding but its deliberate public engagement campaigns. These helped to dispel mistrust while clearly distinguishing genome editing from conventional GMOs. Perhaps crucially, the Korean government streamlined approvals specifically for CRISPR-based products, cutting the average time from research to field trials to just two years. In India, despite regulatory protections outlined in laws like the Environmental Protection Act and the Rules for the Manufacture, Use, Import, Export, and Storage of Hazardous Microorganisms (1989), the timeline from lab innovation to farm application routinely stretches to a decade or more.

The Real Risks: Funding and Public Trust

Even with TnpB’s promise, three systemic flaws loom large. First, whether the government will allocate sufficient funding to operationalize genome editing at scale remains uncertain. Agricultural R&D spending has stagnated at close to 0.3% of GDP, far lower than even other emerging economies. Second, India’s seed supply chains, dominated by informal networks, remain a weak link in ensuring the reach of scientifically advanced varieties. Third, regulatory capture by large firms cannot be ruled out. Would the indigenous TnpB platform benefit farmers universally, or simply shift the monopoly from international corporations to domestic elites like Kaveri Seeds or Mahyco?

The irony here is that ICAR’s ambitions could falter not because of flawed science, but flawed systems. Unless India's bioeconomy priorities are synchronized with equity concerns, "indigenous" may become just another buzzword. For TnpB to succeed, the government must not only simplify biosafety statutes but also invest heavily in extension services, farmer awareness programs, and decentralized R&D hubs—a tall order in the immediate term.

Prelims Practice Questions

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions